|
|
|
|
||
Re: Less than 400k shares traded; what's up PGENers?My dearest Mabel This post is as bad as any of my worst :). How could you ? You conclude your post with : "An investor might want to take a peek at INO’s stock price reaction to their data release on their rrp vaccine candidate. It does not bode well for Precigen. " Let's have a quick look at the Facts please : October 12, 2022, day before INO news . . .. stock closes at $1.63 October 13, 2022, day of the INO news . . .. stock closes at $1.70. up .07 October 14, 2022, day one after the INO news . . .. stock closes at $1.56. down .14 October 17, 2022, day two after INO news . . .. stock closes at $1.83. up .27 October 18, 2022, day three after the INO news . . .. stock closes at $1.80. down .03 October 19, 2022, day four after the INO news . . .. 11 a.m. stock at $1.73. down .07 So is it fair to say that INO is up ten cents since the day before the news was released ? . . .. which is about 6% And that during that timeframe the DOW rose 1,338 thru 11 a.m or about 4.5% PGEN during the same time frame has fallen from $1.81 to $1.80 at 11 a.m. today. Does anyone besides Mabel and Ubmmg find this difference significant ? ? ? And the Motley Fool service had a different possible explanation for INO's recent advance which differs from Mabel . . . .. so they are obviously clueless too :) Why Inovio Pharmaceuticals' Shares Jumped 17.31% on MondayBy Jim Halley – Oct 17, 2022 at 5:59PM KEY POINTS
Should you invest $1,000 in Inovio Pharmaceuticals right now? NASDAQ: INOInovio PharmaceuticalsMarket Cap $449M Today's Change (-1.94%) -$0.04 Current Price $1.76 Price as of October 19, 2022, 9:38 a.m. ET You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More The stock jumped Monday despite no news from the company.What happenedShares of Inovio Pharmaceuticals (INO -1.94%) rose 17.31% on Monday. The clinical-stage biotech company specializes in developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV (human papillomavirus), the most common sexually transmitted infection in the United States. NASDAQ: INOInovio Pharmaceuticals Today's Change (-1.94%) -$0.04 Current Price $1.76 Inovio's stock closed at $1.56 on Friday, then opened on Monday at $1.63. its stock rose to as high as $1.865 shortly before the close and finished the day at $1.83. Inovio has a 52-week low of $1.38 and a 52-week high of $7.77, and is down more than 63% this year. So whatMonday's jump was an odd move, considering the company hasn't released any news since it announced, on Thursday, positive results from the company's phase 1/2 trial for INO-3107 to treat HPV 6 and HPV 11-associated recurrent respiratory papillomatosis (RRP) in adults. It's possible the market was just slow in reacting to that news and on an up day for the S&P 500 on Monday, just needed an excuse to push Inovio's shares higher. There's also the chance the market is reacting to news that U.S. health authorities are pushing for COVID-19 booster shots. Inovio has nine therapies in its pipeline, including therapies to treat Ebola and prostate cancer, and a potential COVID-19 booster, INO-480. It's also possible that an Ebola outbreak in Uganda might be driving the stock's rise, though the company's Ebola booster vaccine, INO-4201, is still in phase 1 trials. Now whatIt's important to remember that Inovio has very little income and no marketed drugs yet. It may be a good long-term choice, but there's plenty of risk there because of uncertainties. On top of that, the company, even with recent cutbacks, says it has enough cash to fund its operations only through the third quarter of 2024. In the second quarter, the company reported revenue of $784,000, up from $273,000 for the same period in 2021. The company also reported a net loss of $108.5 million or $0.46 per share, compared to a loss of $82.1 million or $0.39 per share in the second quarter of 2021. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
51513 | Re: Less than 400k shares traded; what's up PGENers? | Mabel | 0 | 10/19/2022 11:35:23 AM |